000
| 02546cam 2200349za 4500 |
---|
001 | 9.833902 |
---|
003 | CaOODSP |
---|
005 | 20221107150321 |
---|
007 | cr ||||||||||| |
---|
008 | 170320s2017 onc #ob f000 0 eng d |
---|
020 | |a978-0-660-08004-8 |
---|
040 | |aCaOODSP|beng |
---|
043 | |an-cn--- |
---|
086 | 1 |aHP40-157/2017E-PDF |
---|
245 | 00|aUpdated recommendations on human papillomavirus (HPV) vaccines |h[electronic resource] : |b9-valent HPV vaccine and clarification of minimum intervals between doses in the HPV immunization schedule. |
---|
246 | 1 |iAt head of title: |aAdvisory committee statement (ACS) - National Advisory Committee on Immunization (NACI) |
---|
246 | 30|a9-valent HPV vaccine and clarification of minimum intervals between doses in the HPV immunization schedule |
---|
260 | |a[Ottawa] : |bPublic Health Agency of Canada, |c2017. |
---|
300 | |a55 p. |
---|
500 | |aIssued also in HTML format. |
---|
500 | |aIssued also in French under title: Recommandations mises à jour sur les vaccins contre le virus du papillome humain (VPH) : vaccin nonavalent contre le VPH et précisions sur les intervalles minimums entre les doses dans le calendrier d'immunisation contre le VPH. |
---|
504 | |aIncludes bibliographical references. |
---|
520 | |a"In February 2015, a nine-valent human papillomavirus vaccine (HPV9) (Gardasil®9, Merck Canada, Inc.) was authorized for use in Canada. The purpose of this statement is to summarize information on this vaccine and to provide evidence-based recommendations on its use in the context of recommendations for all HPV vaccines currently authorized for use in Canada. In addition, this statement will clarify minimum intervals between doses of HPV vaccines for two-dose and three-dose HPV immunization schedules"--Introduction, p. 7. |
---|
692 | 07|2gccst|aSexually transmitted diseases |
---|
692 | 07|2gccst|aImmunization |
---|
710 | 1 |aCanada. |bNational Advisory Committee on Immunization. |
---|
710 | 2 |aPublic Health Agency of Canada. |
---|
775 | 08|tRecommandations mises à jour sur les vaccins contre le virus du papillome humain (VPH) |w(CaOODSP)9.833903 |
---|
795 | |tUpdated recommendations on human papillomavirus (HPV) vaccines |w(CaOODSP)9.818011 |
---|
856 | 40|qPDF|s1.18 MB|uhttps://publications.gc.ca/collections/collection_2017/aspc-phac/HP40-157-2017-eng.pdf |
---|
856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/public-health/services/publications/healthy-living/9-valent-hpv-vaccine-clarification-minimum-intervals-between-doses-in-hpv-immunization-schedule.html |
---|